TNFRSF11B and diabetes mellitus: Eight weeks CS or metformin administration decreased the levels of ALP, CTX-1, TRACP 5b, osteocalcin, PINP and RANKL (CS vs. diabetes, p < 0.01), increased the levels of RUNX 2 and OPG (CS vs. diabetes, p < 0.01, Met vs. diabetes, p < 0.05).